News & Notes
- OTT Event: Save the Date for this Year's Annual Celebration ... View More
- Emory Start-up:: AKESOgen makes Inc. Magazines list of fastest growing private companies ... View More
- Emory Sponsored Research: Record $572.4 million in external research funding for 2015 ... View More
- Emory Start-up: Cambium Awarded National Eye Institute Grant ... View More
- ORA Changes: Important Changes in OSP Contract Administration ... View More
P-Selectin Inhibitor for Sickle Cell TreatmentRichard Cummings, PhD
Sickle cell disease affects millions of people throughout the world, particularly black and Hispanic communities. The Centers for Disease Control and Prevention (CDC) estimate that approximately 90,000 to 100,000 Americans have sickle cell disease. Globally, this number is in the millions. Yet there is no widely available cure for the disease. Treatments for sickle cell disease primarily consist of managing the symptoms that come along with the disease, such as pain, anemia and stroke, instead of treating the disease itself.